| Similar Articles |
|---|
 |
The Motley Fool
January 3, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Telik... Gorman-Rupp... China Netcom... Penson Worldwide...   |
The Motley Fool
January 24, 2007
Matt Koppenheffer |
The 5-Sigma Report These stocks experienced serious volatility in the past week: Mills... Rackable Systems... Genesis HealthCare... GPC Biotech... Total System Services... |
The Motley Fool
December 19, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Nuvelo... Hubbell... EPIX Pharmaceuticals... Spartech... Companhia de Saneamento Basico do Estado de Sao Paulo... etc. |
The Motley Fool
January 31, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that experienced serious volatility last week. 21st Century Insurance Group... LECG... Novelis... National Interstate Group... Technitrol... |
The Motley Fool
August 30, 2005
Charly Travers |
A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note. |
The Motley Fool
December 12, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer... |
BusinessWeek
September 5, 2005
Gene G. Marcial |
AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
The Motley Fool
March 20, 2007
Brian Lawler |
Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results. |
The Motley Fool
January 27, 2004
David Nierengarten |
Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company. |
The Motley Fool
March 28, 2007
Brian Lawler |
AtheroGenics Splices the Data Shares of AtheroGenics will continue to be volatile in the next couple of months as investors await the probable discontinuation of the company's partnership with AstraZeneca. |
The Motley Fool
July 30, 2007
Brian Lawler |
AtheroGenics Follows a New Route AtheroGenics gives more details on the path forward for its lead drug. The drugmaker is trading at a low $70 million valuation, but investors who buy into shares today shouldn't get their hopes up for the outcome. |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
BusinessWeek
January 20, 2011
Bruce Einhorn |
Chinese Chipmaker SMIC: Profitability Ahead A turnaround at Semiconductor Manufacturing International could help China finally become a player in the global semiconductor industry |
The Motley Fool
April 23, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Spansion... Briggs & Stratton... Solarfun Power Holdings... Labor Ready... etc. |
The Motley Fool
June 4, 2007
Brian Lawler |
Is AtheroGenics Grasping at Straws? The pharmaceutical announces the path forward for its lead drug. Investors, take note. |
The Motley Fool
March 20, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Accredited Home Lenders... Newcastle Investment... NovaStar Financial... Fremont General... American Oriental Bioengineering... |
The Motley Fool
February 15, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week: Nxstage Medical ... New Century Financial... Domino's Pizza... TeleTech Holdings... Omniture... |
The Motley Fool
November 29, 2006
Matt Koppenheffer |
The 5-Sigma Report In a 5-sigma move, a stock has a one-day price move that is five standard deviations or more from the stock's average one-day change. Here are more stocks that defy the averages. Blockbuster... J Crew Group... etc. |
The Motley Fool
December 5, 2006
Matt Koppenheffer |
The 5-Sigma Report What caused the biggest moves of the week? Abington Community Bancorp... Dress Barn... Dynavax Technologies... DSW... |
Pharmaceutical Executive
October 1, 2006
Rob Scott |
Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug." |
InternetNews
February 12, 2004
Colin Haley |
Chipmaker IPOs Signal Sector Resurgence China's SMIC (Semiconductor Manufacturing International) files paperwork to go public and California's Atheros ups its planned offering price. |
The Motley Fool
October 25, 2005
Tim Beyers |
Who's Buying Now? Data management, heart drugs, and medicine for tots top this week's list of insider buys: Acxiom... AtheroGenics... ITT Educational Services... Natus Medical... Tessco Technologies... etc. |
The Motley Fool
January 26, 2007
Dan Bloom |
Texas Instruments' Surprising Move The firm decides to end some in-house manufacturing. Because this is the world's third-largest semiconductor company, one must wonder what the decision means for the future of captive manufacturing capacity. Investors, take note. |
InternetNews
December 22, 2003
Roy Mark |
TSMC Accuses Chinese Rival of Pirating Taiwan-based semiconductor manufacturer TSMC says a Chinese rival pirated employees and trade secrets. |
